June 27 (Reuters) - Biogen Inc BIIB.O:
NEW DATA FOR NUSINERSEN UNDERSCORE BIOGEN’S COMMITMENT TO ADVANCING CLINICAL RESEARCH TO IMPROVE OUTCOMES IN SMA
BIOGEN - SAFETY PROFILE OF HIGHER DOSE REGIMEN OF NUSINERSEN IS BROADLY CONSISTENT WITH KNOWN SAFETY PROFILE OF 12 MG SPINRAZA
Source text: ID:nGNE3vRdZL
Further company coverage: BIIB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.